Business Wire

U.S. Ambassador Johnson and UK’s Sir Nicholas Soames to join Bermuda Premier at Executive Forum in London

Share

The United States Ambassador to the United Kingdom (UK), Robert Wood Johnson, and the UK’s Rt. Hon. Sir Nicholas Soames, former defence minister and former Conservative Member of Parliament for Mid Sussex, will join Bermuda’s Premier, the Hon. E. David Burt, JP, MP, at an Executive Forum in London this month to highlight the historic and successful economic relationship that exists between Bermuda, the U.S. and the UK.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20191113005627/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Bermuda Executive Forum London 2019 opening panel. (Photo: Business Wire)

The keynote conversation between Ambassador Johnson, Sir Nicholas Soames and the Premier will explore the implications of global trends, address key challenges from Brexit to U.S. tax reform, and shed light on new opportunities to further develop economic ties. The discussion will be moderated by Fiona Luck, a Non-Executive Director on the Lloyd’s of London Franchise Board, whose more than 30 years’ experience in insurance and reinsurance will bring valuable insights from Bermuda’s traditional powerhouse industry, a significant contributor to the world’s economy.

Under the theme ‘Navigating Disruption for Positive Change’, the Bermuda Executive Forum London takes place Tuesday, November 26 and is hosted by the Bermuda Business Development Agency (BDA). It will bring together government officials, regulators and industry leaders for a full-day agenda of engaging panel discussions and keynotes across a range of sectors including re/insurance, asset management, family offices, financial services and technology. A networking reception will close the event in the evening.

“We look forward to welcoming Ambassador Johnson and Sir Nicholas Soames to our forum in London. Their participation, alongside our Premier, will ensure a dynamic and informative start to the day,” said Roland Andy Burrows, CEO of the BDA. “The U.S. and the UK are highly valued Bermuda partners and we have long enjoyed robust, mutually beneficial relationships that continue to thrive in many areas. As world-leading and innovative financial centres there’s clearly a lot of common ground for collaboration where we can work together to grow business and investment for the benefit of all.”

Ambassador Johnson was nominated by President Trump on June 22, 2017. He made his first official visit to Bermuda in July this year when he spoke about the strength and long-term nature of Bermuda’s relationship with the U.S. and expressed his admiration for the island’s unique capabilities and world-class expertise.

A prominent businessman and philanthropist, Ambassador Johnson served for more than 30 years as the Chairman and CEO of The Johnson Company, a private asset management firm founded in 1978, and as the Chairman and CEO of the New York Jets football team and New York Jets Foundation. He is the Founding Chairman of the Lupus Research Alliance and worked for many years with the Juvenile Diabetes Research Foundation.

Former Conservative Party grandee and grandson of the great wartime leader Sir Winston Churchill, Sir Nicholas served until recently as the Member of Parliament for Mid Sussex. Prior to that, he was the UK Minister of State for the Armed Forces from 1994-1997. Having previously worked as a stockbroker and on the staff of a U.S. Senator in Washington D.C, he has specialist knowledge in the fields of Europe, defence, international affairs, aviation and trade and industry. He also has a longstanding involvement in the Insurance and Reinsurance business as a Senior Advisor to Marsh the Global Leader in Broking and Risk Management. In March earlier this year, Sir Nicholas met with Premier Burt as part of a wider Bermuda Government trip to the UK and Brussels.

Mr Burrows added, “Against a backdrop of global economic and digital disruption, our event provides a platform for an open dialogue on how best to embrace change to bring about positive transformations and future growth. It is an ideal opportunity to directly engage with partners in the UK market, to share knowledge and forge new connections with prospective businesses and investors who would benefit from Bermuda’s global connectivity combined with its quality, stability and ease of doing business.”

The BDA forum builds on a two-day event held in London last year opened by Premier Burt with more than 50 experts as speakers and panellists. The event attracted close to 200 delegates encompassing a wide range of industries, and featured the UK’s Chris Holmes, Lord of Richmond MBE, and Bermudian Chief Executive of American International Group (AIG), Brian Duperreault.

To register for the Bermuda Executive Forum London 2019, click here.

CONNECTING BUSINESS

The BDA encourages direct investment and helps companies start up, re-locate or expand their operations in our premier jurisdiction. An independent, public-private partnership, we connect you to industry professionals, regulatory officials, and key contacts in the Bermuda government to assist domicile decisions. Our goal? To make doing business in Bermuda smooth and beneficial.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

MEDIA CONTACT:
Nicola Stevens
Director of Communications and PR
nstevens@bda.bm
+1 441 292 7774

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Sonrotoclax Data at ASH 2025 Confirm Foundational Potential Across B-cell Malignancies8.12.2025 01:00:00 EET | Press release

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data on sonrotoclax, a next-generation investigational BCL2 inhibitor, demonstrating meaningful clinical benefit as monotherapy and in combination across B-cell malignancies. These data were featured at the 67th American Society of Hematology (ASH) Annual Meeting & Exposition in Orlando, Florida. The five presentations highlight durable responses in heavily pretreated patients with relapsed/refractory (R/R) mantle cell lymphoma (MCL) and additional studies showing deep, rapid, and sustained undetectable minimal residual disease (uMRD) rates with sonrotoclax-based combinations in patients with treatment-naive chronic lymphocytic leukemia (CLL), highlighting the foundational potential of this medicine. “The data we’re presenting at ASH 2025 are redefining what physicians can expect from sonrotoclax as a next-generation BCL2 inhibitor,” said Amit Agarwal, M.D., Ph.D., Chief Medical

Hemato-Oncology Trials: AOP Health Presents New Results at Top Congress ASH7.12.2025 18:00:00 EET | Press release

AOP Health continues to advance its clinical research program in myeloproliferative neoplasms, a special group of rare blood cancers. The company, specialized in rare diseases, presented the results of two scientific investigations at the 67th American Society of Hematology Association (ASH) Annual Meeting 2025 held in Orlando, FL, USA. The results provide new insights in treatment strategies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251207587915/en/ Dr. Martin Steinhart, CEO AOP Health; Photo credit: AOP Health/Studio Koekart ROP-ET and BESREMI PASS One of the clinical studies, ROP-ET, examined the use of ropeginterferon alfa-2b in people with essential thrombocythemia (ET), a disease in which the body produces too many platelets. The trial, a prospective, multicenter, single-arm phase III study, investigated the safety and efficacy of ropeginterferon alfa-2b in ET patients unable to receive available cytoreductive th

CoMotion GLOBAL 2025 Launches in Riyadh: Global Mobility Leaders Unite in Saudi Capital to Chart Urban Future7.12.2025 14:00:00 EET | Press release

Riyadh is rapidly becoming one of the world's most ambitious urban mobility laboratories, where next-generation technologies move from blueprint to real-world deployment on city streets at unprecedented scale. CoMotion GLOBAL 2025, the world's most influential gathering of urban mobility leaders, opens today in Riyadh for a three-day summit bringing together innovators from Africa, Asia, Europe, the Americas, and the Middle East. Running December 7-9, the event will explore how electrification, autonomy, AI-enabled transport, and giga-project urbanism are reshaping cities worldwide. The summit will spotlight everything from high-performance EVs and breakthrough autonomous fleets to emerging-market transport solutions and new mobility models, demonstrating how the Kingdom is opening new pathways for global mobility leadership. Strategic Partnerships Powering the Summit CoMotion GLOBAL 2025 is hosted by the Saudi Conventions & Exhibitions General Authority (SCEGA), supported by key Saudi

Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67 th American Society of Hematology (ASH) Annual Meeting6.12.2025 16:30:00 EET | Press release

Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which Ono obtained exclusive global rights for the development and commercialization of sapablursen. “In the treatment of PV, phlebotomy and cytoreductive therapy are performed as treatments for preventing thrombosis. Phlebotomy is the most common treatment for PV, in which blood

Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 16:30:00 EET | Press release

Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society of Hematology (ASH) Annual Meeting and Exposition. These findings further reinforce rusfertide’s efficacy and safety and demonstrate durability of response, with 61.9% of patients continuously treated with rusfertide maintaining absence of phlebotomy eligibility from baseline to Week 52. “The 52-week data demonstrated the sustained efficacy of rusfertide, reducing the need for patients to receive phlebotomy while maintaining hematocrit control,” said Dr. Andrew T. Kuykendall, M.D., VERIFY Lead Investigator and Associate Member in the Department of Hematology at Moffitt Cancer Center. “The 32-week VERIFY primary results were already promising, and this deeper understanding of the durability of r

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye